Search NLS News

SmiLe Deputy CEO Ulrika Ringdahl takes over as new CEO of SmiLe.

The company has announced the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden to complete initial investigations on the effect of Pila Pharma's lead molecule, XEN-D0501, on Abdominal Aorta Aneurism growth in mice.

Evaxion Biotech has, as anticipated, received a letter dated November 11, 2024, with a delisting determination from Nasdaq Stock Market LLC for failure to maintain stockholders’ equity of at least USD 2.5 million as required by Nasdaq Listing Rule 5550(b).

At the Nordic Pharmacovigilance Day 2024, held on November 13, industry leaders, regulatory experts, and healthcare professionals from across the Nordic region are gathering to explore the latest advancements and challenges in pharmacovigilance.

BIO-Europe 2024 was held at Stockholmsmässan in Älvsjö on November 4-6, and Nordic Life Science asked three Norwegian life science profiles about their impressions and reasons for attending.

Capitainer has announced the establishment of Capitainer Inc. in the United States. This expansion will enhance customer service and streamline order processing for the company’s growing US market, further strengthening Capitainer’s goal to become the gold standard and global leader in self-sampling, the company states.

Combining the strengths of two companies is a way to position against competitors and also become more resilient to a fluctuating financial market.

The life science innovation gap between the EU and its global competitors continues to widen while the number of EU regulations affecting the industry is rising. Are we heading in the right direction?

In a press release from Lif (the trade association for the research-based pharmaceutical industry in Sweden) they state that the strategy needs to be supplemented with the necessary connection to the fact that new medicines and innovations need to be used early on in healthcare.

Kancera has announces the decision to focus its business on developing the company’s fractalkine blocking candidate drugs KAND567 and KAND145 to treat cardiovascular diseases, initially with focus on treatment of ST-elevation myocardial infarction (STEMI).